Patients with compensated hepatitis B-related cirrhosis at Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, were recruited in this prospective study from May 2017 to June 2018. The inclusion criteria were (1) presence of hepatitis B surface antigen for at least six months and (2) cirrhosis detected by liver histology or unequivocal clinical and imaging data. The exclusion criteria were (1) coinfection with hepatitis C virus or other chronic liver diseases; (2) history of liver surgery and liver transplantation; (3) portal or hepatic vein thrombosis detected by imaging techniques; (4) previous treatments with transjugular intrahepatic portosystemic shunts, EVs banding ligations, or nonselective beta-blockers; (5) moderate-to-severe ascites; (6) hepatic encephalopathy; (7) the history or presence of variceal hemorrhage; (8) AST and/or ALT elevation > 5 × the upper limit of normal; (9) right heart failure; and (10) obstructive jaundice. Informed consent was obtained from all participants in this study. All procedures followed the 1964 Declaration of Helsinki and were approved by the Ethics Committee of Shandong Provincial Hospital. This study has been registered in the Chinese Clinical Trial Registry (1900020560).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.